Medtronic
This article was originally published in The Gray Sheet
Executive Summary
Divestiture of non-occlusive arterial pump line to Baxter settles Federal Trade Commission antitrust charges in connection with the company's $106 mil. acquisition of Avecor on March 8, FTC announces March 10. Avecor's perfusion device, which is currently in the early stages of gaining market acceptance, offers consumers advantages over Medtronic's Bio-Pump, FTC notes